Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

Date Posted: 
2017-01-30

NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
Dr. Zoubeidi’s discovery of the protein driving the emergence of NEPC is a timely and important one. It allowed her and her team to use the new genome editing CRISPR technology to turn off the gene producing that protein. They discovered that when it was turned off, the emergence of NEPC was prevented. Her work was published Cancer Discovery.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development